Category Archives: BioUtah News
Johnson & Johnson to Begin COVID-19 Vaccine Clinical Trials in Humans Next Week
Last month, Johnson & Johnson (J&J) announced that its Phase 1/2a in-human clinical trial of its potential COVID-19 vaccine was expected to begin in July – instead of September as initially scheduled. On Thursday, as reported by Fierce Pharma, J&J chief scientific officer Paul Stoffels confirmed the accelerated timeline, saying that the company has seen […]
Pfizer, BioNTech Get FDA Fast Track Status for COVID-19 Vaccines
U.S. Pfizer and Germany’s BioNTech announced Monday that they have received Fast Track designation from the FDA for two COVID-19 vaccine candidates – BNT162b1 and BNT162b2 – part of the companies’ “Project Lightspeed” program. The designation was issued based on promising preliminary data from Phase 1/2 clinical studies. The FDA’s Fast Track designation is intended […]
Alucent Biomedical Announces First Patient Enrolled in Phase 1 Natural Vascular Scaffolding Clinical Trial
Multicenter ACTIVATE I Study to Enroll up to 15 Patients in the U.S. SALT LAKE CITY – May 27, 2020 – (Alucent Biomedical) Alucent Biomedical Inc. announced that it has enrolled the first two patients in ACTIVATE I, a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding […]
BioUtah Mourns Loss of Soft Cell Founder and CEO, John “Brent” Hunt
BioUtah and Utah’s life sciences community mourns the death of one our own, John “Brent” Hunt, age 59. He was founder and CEO of Soft Cell Biological Research (Soft Cell). Soft Cell issued a press release following his passing. According to a report by KSL, he was reported missing on Friday, May 4 after failing […]
Utah’s Control Medical Technology Gets FDA Clearance for New Mechanical Thrombectomy Platform
Control Medical Technology announced on May 7 that the FDA cleared the company’s Control 7 – 11F Mechanical Thrombectomy platform to remove blood clots from peripheral vessels. The device provides clinicians with a more cost-effective tool to remove blood clots. “This FDA clearance quadruples our product offering and improves our ability to help patients,” said […]
IDbyDNA Participates in NIH National COVID-19 Genomics Consortium
The CDC is leading the national SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance initiative (SPHERES) to coordinate SARS-CoV-2 sequencing across the U.S. Utah’s own IDbyDNA will be participating in the effort along with clinical and public health laboratories, academic institutions, and other private sector companies. The SPHERES consortium aims to generate information […]
Silver lining: opportunities can arise from the corona crisis
Author: Anja Petschauer Co-authors: Anna Derschang, Melitta Gilllespie gwSaar has been a member of BioUtah and a trusted partner of the State of Utah for many years. As a German investment promotion agency, we can observe the economic trends developing in our crisis-stricken global economy first-hand. We are honored that BioUtah has asked us to provide […]
BioUtah’s Newest Associate Member: Greg Gunn, Colliers International
BioUtah’s newest Associate Member is Greg Gunn at Colliers International. With over 35 years of experience in commercial real estate, Greg has negotiated over $700 million in leases representing properties anywhere from 1,000 to 145,000 square feet in size. As a Senior Vice President at Colliers International, Greg has been impressed with the growth of […]
